TCG
BMY icon

Transcendent Capital Group’s Bristol-Myers Squibb BMY Stock Holding History

Transcendent Capital Group’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7,461
Closed -$453K – 130
2026
Q1 		$453K Buy
7,461
+1,564
+27% +$91.2K 0.21% 78
2025
Q4 		$318K Buy
+5,897
New +$284K 0.14% 91
2025
Q1 		– Sell
-4,678
Closed -$265K – 127
2024
Q4 		$265K Buy
4,678
+4,486
+2,336% +$251K 0.14% 86
2024
Q3 		$9.93K Buy
+192
New +$9.01K 0.01% 360

Other funds holding BMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Transcendent Capital Group's BMY Position: Q2 2026 in Review

Transcendent Capital Group sold out of Bristol-Myers Squibb (BMY) in Q2 2026, closing a stake of 7,461 shares — an estimated $453K sold.

Transcendent Capital Group first reported a position in BMY in Q3 2024 and held it in 4 quarters. The position peaked at $453K in Q1 2026. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Transcendent Capital Group reported no remaining Bristol-Myers Squibb position as of Q2 2026 after selling out during the quarter.
  • Transcendent Capital Group sold 7,461 Bristol-Myers Squibb shares in Q2 2026, an estimated $453K.
  • Transcendent Capital Group first reported a position in Bristol-Myers Squibb in Q3 2024 and held it in 4 quarters.
  • Transcendent Capital Group's Bristol-Myers Squibb position peaked at $453K in Q1 2026.
  • 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Transcendent Capital Group's 13F filing for Q2 2026, filed 5 Aug 2026.